Abbokinase

This page contains recent news articles, when available, and an overview of Abbokinase but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

ImaRx Therapeutics Reports Business Update and Financial Results ...  -  Mar 31, 2008
Formerly marketed as Abbokinase(R), the FDA approved ImaRx's request to market the product under a new trade name, Kinlytic. The Company acquired urokinase PR Newswire (press release),

Dutton Associates Announces Investment Opinion: ImaRx Therapeutics ...  -  Feb 19, 2008
We believe that the shares represent an attractive value at current depressed levels based on current levels of Abbokinase sales, possible development of WELT ONLINE,

IMRX: Initiates Coverage @ Speculative Buy w/12-Month Price Target ...  -  Feb 19, 2008
ImaRx Therapeutics is currently focusing on expanding its commercialization efforts for its FDA approved product, Abbokinase(R) (urokinase), Trading Markets (press release),

Microbix Announces First Quarter Results  -  Feb 13, 2008
ImaRx currently generates about $3 million in sales of Abbokinase per quarter, and this is projected to grow once a long-term supply is established with Canada NewsWire (press release),

ImaRx eyes 20 job cuts following its tabling of therapy  -  Feb 25, 2008
...said it would halt development of its "microbubble" stroke therapy and instead concentrate efforts boosting sales of an established drug, Abbokinase. Arizona Daily Star,

Cubist Pharma Revises Q4 Earnings To Reflect $1.2 Mln Acquisition ...  -  Feb 13, 2008
ImaRx currently generates about $3 million in sales of Abbokinase per quarter. The company believes that this sales will grow once a long-term supply is RTT News,

IMRX: Manufacturing and Development Agreement w/Microbix for ...  -  Jan 22, 2008
Urokinase is an FDA approved drug currently marketed under the brand name Abbokinase(R). This product is a thrombolytic agent that is used to dissolve blood Trading Markets (press release),

ImaRx and Microbix Sign Letter of Intent to Manufacture and ...  -  Jan 22, 2008
Urokinase is an FDA approved drug currently marketed under the brand name Abbokinase(R). The product has been used to treat patients in the United States CNNMoney.com

ImaRx to shift focus to sale of approved drug  -  Jan 30, 2008
ImaRx acquired urokinase, branded as Abbokinase, from Abbott Laboratories in 2006. Urokinase is an approved treatment for acute massive pulmonary embolism. Arizona Daily Star,

ImaRx, Microbix in drug-making pact  -  Jan 24, 2008
The drug, branded Abbokinase, is federally approved for treatment of patients with acute massive pulmonary embolism, or blood clots in the lungs. Arizona Daily Star,

Microbix to Manufacture and Further Develop ImaRx Compound  -  Jan 22, 2008
The product is currently marketed under the brand name Abbokinase® as aa thrombolytic drug. ImaRx intends to transfer the manufacturing process and NDA to Genetic Engineering News (press release),

Pulmonary Embolism and Infarction  -  Jan 19, 2008
People with massive pulmonary embolism and shock may need clot-dissolving drugs, such as Abbokinase, Kabikinase, or Activase. Those with low blood pressure American Chronicle,

ImaRx to shift focus to building sales  -  Jan 30, 2008
Urokinase, which Abbott marketed under the name Abbokinase, is an approved treatment for acute massive pulmonary embolism, or blood clots in the lungs. Arizona Daily Star,

imarx Therapeutics Provides Business Update and Reports Third ...  -  Nov 8, 2007
Abbokinase® stability studies have been completed and the company believes that the testing results fall within the required specifications for shelf life Business Wire (press release),

imarx narrows earnings' loss  -  Nov 8, 2007
Tucson-based imarx Therapeutics, Inc. narrowed its third-quarter loss by a third as it increased sales with its Abbokinase embolism-treatment drug, Arizona Daily Star,

Euro RSCG Life LM&P Chicago Announces New Assignment from imarx  -  Oct 30, 2007
Euro RSCG Life LM&P Chicago will manage the re-branding of Abbokinase (urokinase), a thrombolytic approved and marketed for the treatment of acute massive PR Newswire (press release),

imarx Therapeutics to Report Third Quarter 2007 Financial Results ...  -  Nov 2, 2007
...imarx Therapeutics’ commercialization efforts are currently focused on its product, Abbokinase®, for the treatment of acute massive pulmonary embolism. Business Wire (press release),

IMRX: Extension and Amendment Agreement with Abbott re $15M Note  -  Oct 29, 2007
...terms of the $15 million non-recourse promissory note, that the Company issued to Abbott in connection with the Company's acquisition of Abbokinase(R). Trading Markets (press release),

imarx Therapeutics, Inc. at Biotechnology Industry Organization ...  -  Oct 22, 2007
That drug i called Abbokinase. We acquired it from Abbott Laboratories in April of 2006. It has an approved indication for the treatment of acute massive Insurance News Net (press release),

Local biotech journeys from ideas to its IPO  -  Oct 21, 2007
Those sales come from a product that imarx acquired from Abbott Laboratories, a drug known as Abbokinase that dissolves clots and acute pulmonary embolisms. Trading Markets (press release),

ImaRx Therapeutics to Present at BIO Investor Forum on October 11  -  Oct 4, 2007
ImaRx Therapeutics' commercialization efforts are currently focused on its product, Abbokinase(R), for the treatment of acute massive pulmonary embolism. PharmaLive.com (press release),

ImaRx Therapeutics Names Richard Love Chairman - Quick Facts  -  Sep 20, 2007
...would direct the ongoing Sonolysis microbubble clinical program, as well as oversees medical affairs of the company's commercial product, Abbokinase. Trading Markets,

ImaRx Therapeutics Appoints Richard Love As Boards Chairman ...  -  Sep 20, 2007
...the company's ongoing Sonolysis microbubble clinical program, as well as oversee medical affairs of the company's commercial product, Abbokinase. RTT News,

ImaRx Therapeutics Reports Second Quarter 2007 Financial Results ...  -  Aug 29, 2007
The increase in revenues for each of the periods was primarily the result of the commencement of sales of Abbokinase® which accounted for approximately $2.0 Business Wire (press release),

ImaRx narrows second-quarter loss  -  Aug 31, 2007
The company attributed the increase to $2 million in sales of Abbokinase, a clot-busting drug ImaRx acquired last year from Abbott Laboratories. Arizona Daily Star,

ImaRx Therapeutics to Report Second Quarter 2007 Financial Results ...  -  Aug 22, 2007
ImaRx Therapeutics' commercialization efforts are currently focused on its product, Abbokinase(R), for the treatment of acute massive pulmonary embolism. PharmaLive.com (press release),

ImaRx looking at mid-July IPO  -  Jun 26, 2007
Arizona Daily Star,...to rebrand and relaunch Abbokinase, a clot-busting drug ImaRx acquired from Abbott Laboratories in 2006; and to fund new-product development.

ImaRx Therapeutics, Inc. Files Registration Statement for Initial ...  -  May 4, 2007
Genetic Engineering News (press release),ImaRx Therapeutics' commercialization efforts are currently focused on its product, Abbokinase(R), for the treatment of acute massive pulmonary embolism.

:

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.